

RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028

Market Report | 2023-09-15 | 166 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The RNA therapeutics market is projected to grow from USD 13.7 billion in 2023 to USD 18.0 billion by 2028 at a CAGR of 5.6%. The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics (such as RNA aptamers, siRNA, small-activating RNA), and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (siRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics.

"RNA drugs to witness the highest growth during the forecast period."

Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented the majority of the market share, whereas the RNA drugs segment registered the highest growth rate during the forecast period (2023-2028). The growth of the RNA therapeutics drugs market is propelled by a surge in technological advancements in RNA synthesis and drug delivery. The increasing number of FDA approvals for RNA-based drugs and robust increase in the pipeline are attributive to the segment's lucrative growth. Regulatory approvals of RNA-based drugs, such as Patisiran, Lumasiran, and Viltolarsen, and their successful commercialization have encouraged several therapeutics manufacturers to invest in this space.

"The mRNA therapeutics segment accounted for the largest share in the RNA therapeutics market in 2022."

Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. The mRNA therapeutics segment accounted for the largest share of the RNA therapeutics market in 2022. The success of mRNA-based COVID-19 vaccines has also demonstrated the potential of mRNA technology in developing effective vaccines against infectious diseases, leading to increased interest and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

investment in mRNA therapeutics. In August 2023, CARsgen Therapeutics Holdings collaborated with Moderna, Inc. to investigate CARsgen's investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna's investigational Claudin18.2 mRNA cancer vaccine.

?

"Rare genetic/hereditary diseases have emerged as a lucrative segment in the RNA therapeutics market."

Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. Rare genetic diseases, often characterized by their limited prevalence and challenging treatment paradigms, create opportunities for the innovative potential of RNA-based interventions. RNA therapeutics offer a unique avenue to address these rare genetic disorders by precisely targeting the underlying genetic mutations that are responsible for the diseases. Through techniques such as gene silencing using small interfering RNAs (siRNAs) or gene editing using CRISPR/Cas9, RNA therapeutics correct or mitigate the genetic abnormalities causing these conditions.

Europe dominates the global RNA therapeutics market throughout the forecast period.

The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with the highest share of revenue in this segment in 2022. North America has emerged as the fastest-growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs, is highest in 2022, and this is set to continue through the forecast period.

Breakdown of supply-side primary interviews by company type, designation, and region:

- By Respondent: Supply Side (70%), Demand side (30%)
- By Designation: C-level (55%), Director-level (20%), and Others (25%)
- By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report

- [] Moderna, Inc. (US)
- [] Alnylam Pharmaceuticals, Inc. (US)
- [] Pfizer Inc. (US)
- [] Novartis AG (Switzerland)
- [] Ionis Pharmaceuticals, Inc. (US)
- [] Sarepta Therapeutics, Inc. (US)
- [] Sanofi (France)
- [] Arrowhead Pharmaceuticals, Inc. (US)
- [] BioNtech SE (Germany)
- [] Orna Therapeutics (US)
- [] CRISPR Therapeutics (Switzerland)
- [] Silence Therapeutics (UK)
- [] Astellas Pharma Inc. (Japan)
- [] CureVac SE (Germany)
- [] Sirnaomics (US)
- [] Arcturus Therapeutics Inc. (US)
- [] Arbutus Biopharma (US)

Research Coverage

This report studies the RNA therapeutics market based on product, type, indication, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total RNA therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Reasons to Buy the Report:

The report provides insights on the following pointers:

- **Market Drivers:** The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines.
- **Market Penetration:** Comprehensive information on RNA therapeutics offered by the top 17-20 players in the market. The report analyzes the RNA therapeutics market by product, type, indication, end user, and region.
- **Market Development:** Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of RNA therapeutics/end users across key geographic regions.
- **Market Diversification:** Exhaustive information about untapped geographies, recent developments, and investments in the gene editing market
- **Competitive Assessment:** In-depth assessment of market shares and strategies of the leading players in the RNA therapeutics market

Table of Contents:

1	INTRODUCTION	24
1.1	STUDY OBJECTIVES	24
1.2	MARKET DEFINITION	24
1.2.1	INCLUSIONS AND EXCLUSIONS	24
1.3	MARKET SCOPE	25
1.3.1	YEARS CONSIDERED	25
1.4	CURRENCY CONSIDERED	26
1.5	RESEARCH LIMITATIONS	26
1.6	STAKEHOLDERS	26
1.6.1	RECESSION IMPACT: RNA THERAPEUTICS MARKET	27
2	RESEARCH METHODOLOGY	28
2.1	RESEARCH DATA	28
FIGURE 1	RESEARCH DESIGN	28
2.1.1	SECONDARY DATA	29
2.1.2	PRIMARY DATA	29
FIGURE 2	BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET	30
2.2	MARKET ESTIMATION METHODOLOGY	30
FIGURE 3	RNA THERAPEUTICS MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022	30
FIGURE 4	MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022	31
2.2.1	INSIGHTS FROM PRIMARY EXPERTS	32
FIGURE 5	MARKET SIZE VALIDATION FROM PRIMARY SOURCES	32
2.3	MARKET GROWTH RATE PROJECTION	33
FIGURE 6	RNA THERAPEUTICS MARKET (SUPPLY SIDE): CAGR PROJECTIONS	34
FIGURE 7	GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: RNA THERAPEUTICS MARKET	34
2.4	MARKET ESTIMATION AND DATA TRIANGULATION	35
FIGURE 8	DATA TRIANGULATION METHODOLOGY	35
2.5	STUDY ASSUMPTIONS	35
2.6	RISK ANALYSIS	36
2.7	IMPACT OF ECONOMIC RECESSION ON RNA THERAPEUTICS MARKET	36
TABLE 1	GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)	36

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 2	US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	36
TABLE 3	US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	37
3	EXECUTIVE SUMMARY	38
FIGURE 9	RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	38
FIGURE 10	RNA THERAPEUTICS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)	39
FIGURE 11	RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)	39
FIGURE 12	RNA THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	40
FIGURE 13	REGIONAL SNAPSHOT: RNA THERAPEUTICS MARKET	41
4	PREMIUM INSIGHTS	42
4.1	RNA THERAPEUTICS MARKET OVERVIEW	42
FIGURE 14	GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET	42
4.2	NORTH AMERICA: RNA THERAPEUTICS MARKET SHARE, BY PRODUCT AND COUNTRY (2022)	43
FIGURE 15	VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA THERAPEUTICS MARKET IN 2022	43
4.3	NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)	43
FIGURE 16	INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN RNA THERAPEUTICS MARKET DURING FORECAST PERIOD	43
5	MARKET OVERVIEW	44
5.1	INTRODUCTION	44
5.2	MARKET DYNAMICS	44
FIGURE 17	DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET	44
TABLE 4	IMPACT ANALYSIS: RNA THERAPEUTICS MARKET	45
5.2.1	DRIVERS	45
5.2.1.1	Increasing partnerships and collaborations between market players and RNA technology manufacturers	45
5.2.1.2	Increasing number of novel modalities for RNA therapeutics	46
5.2.1.3	Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines	47
5.2.2	RESTRAINTS	48
5.2.2.1	Discontinuation or recalls of RNA therapeutic products	48
TABLE 5	LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED	48
5.2.3	OPPORTUNITIES	49
5.2.3.1	Higher progress in development of RNA aptamer-based therapeutics	49
TABLE 6	RNA APTAMERS UNDER CLINICAL DEVELOPMENT	49
5.2.4	CHALLENGES	50
5.2.4.1	Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA	50
5.3	TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING)	51
5.3.1	PARAMETERS OF MANUFACTURING	51
5.3.2	CIRCULAR RNA ENGINEERING	51
5.4	PIPELINE ANALYSIS	52
FIGURE 18	PIPELINE THERAPIES, BY CATEGORY, 2022	52
5.4.1	PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5)	52
5.4.1.1	Moderna, Inc.	52
TABLE 7	PIPELINE CANDIDATES OF MODERNA, INC.	52
5.4.1.2	Pfizer, Inc.	54
TABLE 8	PIPELINE CANDIDATES OF PFIZER INC.	54
5.4.1.3	Alnylam Pharmaceuticals, Inc.	54
TABLE 9	PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC.	54
5.4.1.4	Novartis AG	55
TABLE 10	PIPELINE CANDIDATES OF NOVARTIS AG	55
5.4.1.5	Ionis Pharmaceuticals, Inc.	55

TABLE 11	PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC.	55
5.5	PORTER'S FIVE FORCES ANALYSIS	56
TABLE 12	PORTER'S FIVE FORCES ANALYSIS: RNA THERAPEUTICS MARKET	56
5.5.1	THREAT OF NEW ENTRANTS	56
5.5.2	THREAT OF SUBSTITUTES	57
5.5.3	BARGAINING POWER OF BUYERS	57
5.5.4	BARGAINING POWER OF SUPPLIERS	57
5.5.5	INTENSITY OF COMPETITIVE RIVALRY	57
5.6	REGULATORY ANALYSIS	58
TABLE 13	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	58
TABLE 14	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	58
TABLE 15	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	59
TABLE 16	REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	59
5.7	VALUE CHAIN ANALYSIS	60
FIGURE 19	VALUE CHAIN ANALYSIS OF RNA THERAPEUTICS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE	60
5.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	61
FIGURE 20	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	61
5.9	KEY STAKEHOLDERS AND BUYING CRITERIA	61
5.9.1	KEY STAKEHOLDERS IN BUYING PROCESS	61
FIGURE 21	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS	61
5.9.2	BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES	62
FIGURE 22	KEY BUYING CRITERIA FOR END USERS	62
5.10	PRICING ANALYSIS	62
5.10.1	PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT	62
TABLE 17	AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION	62
5.10.2	PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS	63
5.11	KEY CONFERENCES AND EVENTS (2023-2024)	63
TABLE 18	KEY CONFERENCES AND EVENTS IN RNA THERAPEUTICS MARKET (2023-2024)	63
5.12	ECOSYSTEM MARKET MAP	64
6	RNA THERAPEUTICS MARKET, BY PRODUCT	65
6.1	INTRODUCTION	66
TABLE 19	RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	66
6.2	VACCINES	66
6.2.1	INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET	66
TABLE 20	RNA THERAPEUTICS MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)	67
TABLE 21	NORTH AMERICA: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)	67
TABLE 22	EUROPE: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)	67
TABLE 23	ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)	68
6.3	DRUGS	68
6.3.1	GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET	68
TABLE 24	RNA THERAPEUTICS MARKET FOR DRUGS, BY REGION, 2021-2028 (USD MILLION)	68
TABLE 25	NORTH AMERICA: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	69
TABLE 26	EUROPE: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	69
TABLE 27	ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	69
7	RNA THERAPEUTICS MARKET, BY TYPE	70
7.1	INTRODUCTION	71
TABLE 28	RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	71

7.2 mRNA THERAPEUTICS 71

7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET 71

TABLE 29 RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION) 72

TABLE 30 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 73

TABLE 31 EUROPE: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 73

TABLE 32 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 73

7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS 74

7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET 74

TABLE 33 RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION) 74

TABLE 34 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 75

TABLE 35 EUROPE: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 75

TABLE 36 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 75

7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS 76

7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 76

TABLE 37 RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION) 76

TABLE 38 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 77

TABLE 39 EUROPE: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 77

TABLE 40 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) 77

7.5 OTHER THERAPEUTICS 78

8 RNA THERAPEUTICS MARKET, BY INDICATION 79

8.1 INTRODUCTION 80

TABLE 41 RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION) 80

8.2 INFECTIOUS DISEASES 80

8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET 80

TABLE 42 RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION) 81

TABLE 43 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) 81

TABLE 44 EUROPE: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) 81

TABLE 45 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) 82

8.3 RARE GENETIC/HEREDITARY DISEASES 82

8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET 82

TABLE 46 RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021-2028 (USD MILLION) 83

TABLE 47 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) 83

TABLE 48 EUROPE: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) 83

TABLE 49 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) 84

8.4 OTHER INDICATIONS 84

TABLE 50 RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION) 85

TABLE 51 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 85

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 52	EUROPE: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	86
TABLE 53	ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	86
9	RNA THERAPEUTICS MARKET, BY END USER	87
9.1	INTRODUCTION	88
TABLE 54	RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	88
9.2	HOSPITALS AND CLINICS	88
9.2.1	INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET	88
TABLE 55	RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)	89
TABLE 56	NORTH AMERICA: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)	89
TABLE 57	EUROPE: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)	89
TABLE 58	ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)	90
9.3	RESEARCH SETTINGS	90
9.3.1	HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH	90
TABLE 59	RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY REGION, 2021-2028 (USD MILLION)	91
TABLE 60	NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)	91
TABLE 61	EUROPE: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)	91
TABLE 62	ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)	92
10	RNA THERAPEUTICS MARKET, BY REGION	93
10.1	INTRODUCTION	94
TABLE 63	RNA THERAPEUTICS MARKET, BY REGION, 2021-2028 (USD MILLION)	94
10.2	NORTH AMERICA	94
FIGURE 23	NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT	95
TABLE 64	NORTH AMERICA: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	95
TABLE 65	NORTH AMERICA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	96
TABLE 66	NORTH AMERICA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	96
TABLE 67	NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	96
TABLE 68	NORTH AMERICA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	97
10.2.1	NORTH AMERICA: RECESSION IMPACT	97
10.2.2	US	98
10.2.2.1	Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market	98
TABLE 69	LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA	98
TABLE 70	US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	99
TABLE 71	US: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	99
TABLE 72	US: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	99
TABLE 73	US: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	100
10.2.3	CANADA	100
10.2.3.1	Increasing government initiatives and investments for life science research to drive market	100
TABLE 74	CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	101
TABLE 75	CANADA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	101
TABLE 76	CANADA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	101
TABLE 77	CANADA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	102
10.3	EUROPE	102
TABLE 78	EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	102
TABLE 79	EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	103
TABLE 80	EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	103
TABLE 81	EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	103

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 82	EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	104
10.3.1	EUROPE: RECESSION IMPACT	104
10.3.2	GERMANY	104
10.3.2.1	Rising number of market players and growing public and private funding for research activities to drive market	104
TABLE 83	GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	105
TABLE 84	GERMANY: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	105
TABLE 85	GERMANY: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	106
TABLE 86	GERMANY: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	106
10.3.3	FRANCE	106
10.3.3.1	Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market	106
TABLE 87	FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	107
TABLE 88	FRANCE: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	107
TABLE 89	FRANCE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	107
TABLE 90	FRANCE: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	108
10.3.4	UK	108
10.3.4.1	Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market	108
TABLE 91	UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	109
TABLE 92	UK: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	109
TABLE 93	UK: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	109
TABLE 94	UK: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	110
10.3.5	REST OF EUROPE	110
TABLE 95	REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	110
TABLE 96	REST OF EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	111
TABLE 97	REST OF EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	111
TABLE 98	REST OF EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	111
10.4	ASIA PACIFIC	112
FIGURE 24	ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT	113
TABLE 99	ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	114
TABLE 100	ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	114
TABLE 101	ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	114
TABLE 102	ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	115
TABLE 103	ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	115
10.4.1	ASIA PACIFIC: RECESSION IMPACT	115
10.4.2	JAPAN	116
10.4.2.1	Increasing geriatric population and rising government initiatives for drug innovation to drive market	116
TABLE 104	JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	116
TABLE 105	JAPAN: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	117
TABLE 106	JAPAN: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	117
TABLE 107	JAPAN: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	117
10.4.3	CHINA	118
10.4.3.1	Low manufacturing costs and increased number of R&D activities to drive market	118
TABLE 108	CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	118
TABLE 109	CHINA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	119
TABLE 110	CHINA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	119
TABLE 111	CHINA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	119
10.4.4	SOUTH KOREA	120
10.4.4.1	Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market	120

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 112	SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	120
TABLE 113	SOUTH KOREA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	120
TABLE 114	SOUTH KOREA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	121
TABLE 115	SOUTH KOREA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	121
10.4.5	REST OF ASIA PACIFIC	121
TABLE 116	REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	122
TABLE 117	REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	122
TABLE 118	REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	122
TABLE 119	REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	123
10.5	REST OF THE WORLD	123
TABLE 120	REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	123
TABLE 121	REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)	124
TABLE 122	REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)	124
TABLE 123	REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	124
11	COMPETITIVE LANDSCAPE	125
11.1	OVERVIEW	125
11.2	KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET	126
FIGURE 25	KEY PLAYER STRATEGIES IN RNA THERAPEUTICS MARKET, 2021-2023	126
11.3	MARKET SHARE ANALYSIS	127
FIGURE 26	MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS MARKET, 2022	127
TABLE 124	DEGREE OF COMPETITION: RNA THERAPEUTICS MARKET	127
11.4	REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS	129
FIGURE 27	REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS MARKET, 2020-2022	129
11.5	COMPANY EVALUATION MATRIX FOR KEY PLAYERS	129
11.5.1	STARS	129
11.5.2	EMERGING LEADERS	130
11.5.3	PERVASIVE PLAYERS	130
11.5.4	PARTICIPANTS	130
FIGURE 28	COMPANY EVALUATION MATRIX FOR KEY PLAYERS: RNA THERAPEUTICS MARKET, 2022	131
11.6	COMPANY EVALUATION MATRIX FOR START-UPS/SMES	132
11.6.1	PROGRESSIVE COMPANIES	132
11.6.2	STARTING BLOCKS	132
11.6.3	DYNAMIC COMPANIES	132
11.6.4	RESPONSIVE COMPANIES	132
FIGURE 29	COMPANY EVALUATION MATRIX FOR START-UPS/SMES: RNA THERAPEUTICS MARKET, 2022	133
11.7	COMPETITIVE BENCHMARKING	134
TABLE 125	DETAILED LIST OF KEY START-UPS/SMES: RNA THERAPEUTICS MARKET	134
11.8	COMPETITIVE SCENARIOS AND TRENDS	135
11.8.1	KEY PRODUCT APPROVALS	135
TABLE 126	KEY PRODUCT APPROVALS, JANUARY 2021-AUGUST 2023	135
11.8.2	KEY DEALS	135
TABLE 127	KEY DEALS, JANUARY 2021-AUGUST 2023	135
11.8.3	OTHER KEY DEVELOPMENTS	136
TABLE 128	OTHER KEY DEVELOPMENTS, JANUARY 2021-AUGUST 2023	136
12	COMPANY PROFILES	137
(Business overview, Products offered, Recent Developments, MNM view)*		
12.1	KEY PLAYERS	137

12.1.1	MODERNA, INC.	137
TABLE 129	MODERNA, INC.: COMPANY OVERVIEW	137
FIGURE 30	MODERNA, INC.: COMPANY SNAPSHOT (2022)	138
12.1.2	ALNYLAM PHARMACEUTICALS, INC.	142
TABLE 130	ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW	142
FIGURE 31	ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)	142
12.1.3	NOVARTIS AG	145
TABLE 131	NOVARTIS AG: COMPANY OVERVIEW	145
FIGURE 32	NOVARTIS AG: COMPANY SNAPSHOT (2022)	146
12.1.4	IONIS PHARMACEUTICALS, INC.	149
TABLE 132	IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW	149
FIGURE 33	IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)	149
12.1.5	SAREPTA THERAPEUTICS, INC.	153
TABLE 133	SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW	153
FIGURE 34	SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022)	153
12.1.6	SANOFI	155
TABLE 134	SANOFI: COMPANY OVERVIEW	155
FIGURE 35	SANOFI: COMPANY SNAPSHOT (2022)	156
12.1.7	PFIZER INC.	158
TABLE 135	PFIZER INC.: COMPANY OVERVIEW	158
FIGURE 36	PFIZER INC.: COMPANY SNAPSHOT (2022)	159
12.2	OTHER PLAYERS	161
12.2.1	ARROWHEAD PHARMACEUTICALS, INC.	161
12.2.2	BIONTECH SE	161
12.2.3	ORNA THERAPEUTICS	162
12.2.4	CRISPR THERAPEUTICS	162
12.2.5	SILENCE THERAPEUTICS	163
12.2.6	ASTELLAS PHARMA INC.	163
12.2.7	CUREVAC SE	164
12.2.8	SIRNAOMICS	164
12.2.9	ARCTURUS THERAPEUTICS, INC.	165
12.2.10	ARBUTUS BIOPHARMA	165
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.		
13	APPENDIX	166
13.1	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	168
13.2	CUSTOMIZATION OPTIONS	170
13.3	RELATED REPORTS	170
13.4	AUTHOR DETAILS	171

RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028

Market Report | 2023-09-15 | 166 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-20

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com